New Zealand markets closed

Hepion Pharmaceuticals, Inc. (HEPA)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
1.0200-0.0400 (-3.77%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.0600
Open1.0900
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.9500 - 1.0600
52-week range0.9000 - 12.0800
Volume30,679
Avg. volume36,493
Market cap5.583M
Beta (5Y monthly)1.70
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial

    EDISON, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that has been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today announced that it has begun wind-down activities in its ASCEND-NASH Trial, while continuing to explore strategic alternatives, as previously announced in December 2023. ASCEND-NASH is a Phase 2b, randomized, m

  • GlobeNewswire

    Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell

    EDISON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, and other chronic diseases, today announced the appointment of Michael Purcell to the Company’s Board of Directors, effective March 5, 2024. Mr. Purcell has more than 37 years of professional experience with Deloitte & Touche LLP, serving as a

  • GlobeNewswire

    Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds

    EDISON, N.J., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial intelligence assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced that it has entered into a definitive agreement for the immediate exercise of an outstanding Series B common stock purchase warrant he